"CentraCare Heart & Vascular Center is one of the largest and most advanced heart and vascular programs in Minnesota, made up of a team of 60+ physicians and advanced practice providers. In 2021, U.S. News & World Report ranked the program #35 in the nation for cardiology and heart surgery. Their expansive service offerings include heart surgery, electrophysiology, heart failure management, vascular care, high cholesterol (lipid) clinic, TVAR and other structural heart services — they are now one of the largest implant sites in the world for Watchman, a device used to treat atrial fibrillation (AFib). With a focus on the prevention, discovery and management of cardiovascular disease, you can find them at 20 locations across Minnesota."

During the past decade, CentraCare Heart and Vascular Center conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 20 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 11 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CentraCare Heart and Vascular Center" #1 sponsor was "Medtronic Cardiac Rhythm and Heart Failure" with 8 trials, followed by "Boston Scientific Corporation" with 5 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "Edwards Lifesciences" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CentraCare Heart and Vascular Center" #1 collaborator was "The Cleveland Clinic" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Cardiovascular Research Foundation, New York" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "CentraCare Heart and Vascular Center" are "Coronary Artery Disease" (5 trials), "Heart Failure" (4 trials), "Atrial Fibrillation" (3 trials), "Aortic Stenosis" (2 trials) and "Bradycardia" (2 trials). Many other conditions were trialed in "CentraCare Heart and Vascular Center" in a lesser frequency.

Most popular intervention types in "CentraCare Heart and Vascular Center" are "Device" (17 trials), "Drug" (12 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Darusentan" (2 trials), "Guanfacine" (2 trials), "Micra Pacemaker Implant" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "CentraCare Heart and Vascular Center" are 32 trials for "All" genders.

Currently, there are NaN active trials in "CentraCare Heart and Vascular Center". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in CentraCare Heart and Vascular Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in CentraCare Heart and Vascular Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 14 trials that are defined as “Not Applicable".